Login to Your Account



Pharmion Acquires Cabrellis: $59M For Lung Cancer Drug

By Randall Osborne


Friday, November 17, 2006
With Vidaza standing firm against competitors, Pharmion Corp. is adding the Phase II anthracycline amrubicin for lung cancer to its pipeline in the $55 million net-of-cash buyout of privately held Cabrellis Pharmaceuticals Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription